Teacher Retirement System of Texas Makes New Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Teacher Retirement System of Texas bought a new stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,125 shares of the biotechnology company’s stock, valued at approximately $91,000.

Several other institutional investors have also made changes to their positions in ATXS. FMR LLC grew its stake in Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after purchasing an additional 1,767,714 shares in the last quarter. Redmile Group LLC acquired a new stake in shares of Astria Therapeutics during the 3rd quarter worth approximately $3,423,000. Charles Schwab Investment Management Inc. increased its holdings in Astria Therapeutics by 152.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company’s stock valued at $3,460,000 after buying an additional 189,727 shares during the period. Raymond James Financial Inc. bought a new position in Astria Therapeutics during the fourth quarter worth about $707,000. Finally, Walleye Capital LLC grew its position in Astria Therapeutics by 69.3% in the third quarter. Walleye Capital LLC now owns 174,581 shares of the biotechnology company’s stock valued at $1,922,000 after acquiring an additional 71,439 shares during the period. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ATXS has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, March 11th. JMP Securities began coverage on Astria Therapeutics in a research note on Friday, January 31st. They issued an “outperform” rating and a $26.00 target price on the stock. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Finally, Wedbush restated an “outperform” rating and set a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Astria Therapeutics presently has an average rating of “Buy” and a consensus target price of $26.60.

Astria Therapeutics Price Performance

NASDAQ:ATXS opened at $5.52 on Thursday. The company has a market cap of $311.52 million, a P/E ratio of -2.64 and a beta of 0.68. The firm’s fifty day moving average price is $6.68 and its two-hundred day moving average price is $9.02. Astria Therapeutics, Inc. has a one year low of $5.24 and a one year high of $12.92.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01. As a group, equities research analysts expect that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.